Internship

Recombinant Mammalian MSAT DSP

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

Framingham, MA, USA

Must be able to relocate to Framingham, MA and work 40 hours/week, Monday-Friday.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Currently pursuing a bachelor's or master's degree in Chemical Engineering, Biochemistry, Biotechnology, or related discipline at an accredited college or university with the expectation that you will complete your current degree by the Spring 2027
  • Must be enrolled in school the semester following your internship/co-op with Sanofi.
  • Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op
  • Must have permanent US work authorization
  • Experience in a biotechnology or pharmaceutical industry laboratory setting
  • Experience with downstream processes at lab, pilot, or production scale including chromatography (e.g. AKTA), tangential flow filtration, or nanofiltration
  • Experience / interest in enzyme reactions and kinetics
  • Experience / interest in mechanistic modeling, coding
  • Strong technical writing and presentation skills
Responsibilities
  • Work on an MSAT development project, to include execution of chromatography and filtration operations, protein stability studies, analytical testing, and data analysis.
  • Collaborate with the MSAT project team; attend regular team meetings and share study progress and results.
  • Participate in design and execution of experiments using small-scale models, analyze and interpret results, and recommend additional experiments.
  • Author internal presentations, protocols, and technical reports, as applicable.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's strong financial performance, as evidenced by its raised 2024 outlook, indicates robust growth and stability.
  • The company's strategic investments in innovative biotech firms, such as Ventyx Biosciences, enhance its pipeline and potential for breakthrough therapies.
  • Sanofi's Dupixent receiving a positive recommendation for expanded use in children demonstrates its leadership in addressing unmet medical needs.

What critics are saying

  • The highly competitive pharmaceutical market requires Sanofi to continuously innovate to maintain its market position.
  • Regulatory challenges in different regions could delay product approvals and impact revenue streams.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts and strategic partnerships, such as with Orano Med for radioligand therapies, set it apart in the competitive pharmaceutical landscape.
  • The company's global reach and focus on patient-centric solutions allow it to effectively navigate diverse regulatory environments and deliver innovative treatments worldwide.
  • Sanofi's investment in sustainable initiatives, like SureChill's 'Cooling as a Service' model, highlights its commitment to addressing healthcare challenges in emerging markets.

Help us improve and share your feedback! Did you find this helpful?